Literature DB >> 2139584

Regional haemodynamic effects of endothelin-1 and endothelin-3 in conscious Long Evans and Brattleboro rats.

S M Gardiner1, A M Compton, T Bennett.   

Abstract

1. The regional haemodynamic effects of bolus doses (4 and 40 pmol) and infusions (12 and 120 pmol h-1) of endothelin-1 and endothelin-3 were assessed in conscious, Long Evans and Brattleboro (i.e. vasopressin-deficient) rats, chronically-instrumented with pulsed Doppler flow probes. 2. In both strains of rat the lower bolus dose of endothelin-1 caused only a slight pressor effect, but there were marked renal and mesenteric vasoconstrictions and hindquarters vasodilatation. 3. The lower bolus dose of endothelin-3 did not affect blood pressure significantly, although the changes in regional haemodynamics were qualitatively similar to those seen following endothelin-1 in Long Evans and Brattleboro rats. 4. The higher dose of endothelin-1 caused an initial hypotension accompanied by substantial hindquarters vasodilatations in Long Evans and Brattleboro rats. Subsequently, in both strains, there was a rise in blood pressure accompanied by renal, mesenteric and hindquarters vasoconstrictions. 5. The higher bolus dose of endothelin-3 caused initial hypotension and hindquarters vasodilatation similar to those seen with endothelin-1. However, the subsequent pressor effect was less with endothelin-3, as was the renal vasoconstriction, and it did not cause any increase in hindquarters vascular resistance. 6. Infusion of endothelin-1 at the lower rate (12 pmol h-1) caused renal and mesenteric vasoconstrictions in both strains of rat, whereas endothelin-3 at this rate caused only mesenteric vasoconstriction. 7. Infusion of endothelin-1 at the higher rate (120 pmol h-1) caused progressive hypertension and vasoconstrictions in all three vascular beds studied; these were similar in both strains of rat. Endothelin-3 had a smaller pressor effect and a lesser constrictor action on the renal and mesenteric vascular beds; it did not constrict the hindquarters vascular bed. 8. These results show, that in conscious Long Evans and Brattleboro rats, the initial depressor effects of the higher bolus doses of endothelin-1 and -3 were similar, and, hence, not influenced by the absence of endogenous vasopressin. Endothelin-1 and -3 appear equipotent in their initial hyperaemic vasodilator effects in the hindquarters vasculature in both strains, making it unlikely that this effect is dependent on the release of atrial natriuretic peptide (ANP), since ANP does not cause significant increases in hindquarters blood flow in Brattleboro rats. The greater delayed pressor effect of endothelin-1 is associated with its more marked vasoconstrictor effects on renal and mesenteric vascular beds and is accentuated, relative to endothelin-3, by the lack of a constrictor effect of endothelin-3 in the hindquarters vasculature.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139584      PMCID: PMC1917519          DOI: 10.1111/j.1476-5381.1990.tb14662.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide.

Authors:  M Yanagisawa; A Inoue; T Ishikawa; Y Kasuya; S Kimura; S Kumagaye; K Nakajima; T X Watanabe; S Sakakibara; K Goto
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

2.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

3.  Regional vasodilation is a prominent feature of the haemodynamic response to endothelin in anaesthetized, spontaneously hypertensive rats.

Authors:  C E Wright; J R Fozard
Journal:  Eur J Pharmacol       Date:  1988-10-11       Impact factor: 4.432

4.  Studies with endothelin-3 and endothelin-1 on rat blood pressure and isolated tissues: evidence for multiple endothelin receptor subtypes.

Authors:  R A Spokes; M A Ghatei; S R Bloom
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

5.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.

Authors:  G de Nucci; R Thomas; P D'Orleans-Juste; E Antunes; C Walder; T D Warner; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  The pharmacological properties of the peptide, endothelin.

Authors:  R M Eglen; A D Michel; N A Sharif; S R Swank; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

7.  Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat.

Authors:  T D Warner; G de Nucci; J R Vane
Journal:  Eur J Pharmacol       Date:  1989-01-17       Impact factor: 4.432

8.  Enhanced release of atrial natriuretic factor by endothelin in atria from hypertensive rats.

Authors:  R J Winquist; A L Scott; G P Vlasuk
Journal:  Hypertension       Date:  1989-07       Impact factor: 10.190

9.  Regional haemodynamic effects of depressor neuropeptides in conscious, unrestrained, Long Evans and Brattleboro rats.

Authors:  S M Gardiner; A M Compton; T Bennett
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

10.  Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat.

Authors:  J R Haywood; R A Shaffer; C Fastenow; G D Fink; M J Brody
Journal:  Am J Physiol       Date:  1981-08
View more
  29 in total

1.  Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre- or post-treatment with glibenclamide.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  Regional and cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats.

Authors:  S M Gardiner; A M Compton; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

3.  Increased endothelin excretion in rats with renal failure induced by partial nephrectomy.

Authors:  D P Brooks; L C Contino; B Storer; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

4.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 5.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

6.  Cross tachyphylaxis to endothelin isopeptide-induced hypotension: a phenomenon not seen with proendothelin.

Authors:  A C Le Monnier de Gouville; I Cavero
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

7.  Effects of NG-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, 5'-N-ethylcarboxamidoadenosine or salbutamol in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

8.  Effects of the neutral endopeptidase inhibitor, SQ 28,603, on regional haemodynamic responses to atrial natriuretic peptide or proendothelin-1 [1-38] in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

9.  Endothelium-dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16-21) and other endothelin-related peptides in the rat.

Authors:  S A Douglas; C R Hiley
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

10.  Response of rabbit ear artery to endothelin-1 during cooling.

Authors:  L Monge; A L García-Villalón; J J Montoya; J L García; B Gómez; G Diéguez
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.